Cohn, Susan L.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine

Neuroblastoma Research and TreatmentsGlioma Diagnosis and Treatment

Cited by 1,835

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 357

Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology

Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases

Cited by 318

Binding of a 40-kDa Protein to the N-myc 3ʹ-Untranslated Region Correlates with Enhanced N-myc Expression in Human Neuroblastoma

Chagnovich, D., & Cohn, S. L. (1996) · Journal of Biological Chemistry

Neuroblastoma Research and TreatmentsRNA Research and Splicing

Cited by 37

Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system

Stricker, T. P., Morales La Madrid, A., Chlenski, A., Guerrero, L., Salwen, H. R., Gosiengfiao, Y., Perlman, E. J., Furman, W., Bahrami, A., Shohet, J. M., et al. (2014) · Molecular Oncology

Neuroblastoma Research and TreatmentsGene expression and cancer classification

Cited by 36